Methotrexate News and Research

RSS
Methotrexate is an antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.

Methotrexate is approved by the Food and Drug Administration (FDA) to be used by itself to treat the following types of gestational trophoblastic tumors, Chorioadenoma destruens, Choriocarcinoma, Hydatidiform mole. Methotrexate is also approved to be used alone or with other drugs to treat acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to keep it from spreading there, and to treat the following, breast cancer, certain types of head and neck cancer, lung cancer, advanced non-Hodgkin lymphoma (NHL), advanced mycosis fungoides (a type of cutaneous T-cell lymphoma), osteosarcoma that has not spread to other parts of the body, following surgery to remove the primary tumor. Methotrexate is also approved to treat the following non-cancer conditions, rheumatoid arthritis, severe psoriasis.
Most DMARDs not linked with the risk of Parkinson's disease in people with rheumatoid arthritis

Most DMARDs not linked with the risk of Parkinson's disease in people with rheumatoid arthritis

Efficacy and safety of mRNA-based SARS-CoV-2 vaccination in immuno-compromised subjects

Efficacy and safety of mRNA-based SARS-CoV-2 vaccination in immuno-compromised subjects

Immune response elicited by SARS-CoV-2 vaccines in infliximab and vedolizumab-treated patients with IBD

Immune response elicited by SARS-CoV-2 vaccines in infliximab and vedolizumab-treated patients with IBD

HSS study provides insight into real-world medication use for treatment of psoriatic arthritis

HSS study provides insight into real-world medication use for treatment of psoriatic arthritis

RA patients taking glucocorticoids or B-cell therapies may have worse COVID-19 vaccine response

RA patients taking glucocorticoids or B-cell therapies may have worse COVID-19 vaccine response

Factors contributing to a weak antibody response to the Pfizer COVID-19 vaccine

Factors contributing to a weak antibody response to the Pfizer COVID-19 vaccine

Study looks at immunosuppressants and COVID vaccine efficacy

Study looks at immunosuppressants and COVID vaccine efficacy

COVID-19 vaccine elicits antibody responses in nearly 9 out of 10 people taking immunosuppressants

COVID-19 vaccine elicits antibody responses in nearly 9 out of 10 people taking immunosuppressants

NIH begins clinical trial to assess extra COVID-19 vaccine dose in people with autoimmune disease

NIH begins clinical trial to assess extra COVID-19 vaccine dose in people with autoimmune disease

New evidence-based resources to guide treatment of plaque psoriasis

New evidence-based resources to guide treatment of plaque psoriasis

Immunogenicity of mRNA vaccine against emerging strains of SARS-CoV-2 in immunocompromised patients

Immunogenicity of mRNA vaccine against emerging strains of SARS-CoV-2 in immunocompromised patients

Breakthrough SARS-CoV-2 infections in patients with systemic rheumatic diseases

Breakthrough SARS-CoV-2 infections in patients with systemic rheumatic diseases

NIH-funded study examines most effective treatment option for pregnancy of unknown location

NIH-funded study examines most effective treatment option for pregnancy of unknown location

Study analyzes uveitis risk after antirheumatic drug withdrawal in children with arthritis

Study analyzes uveitis risk after antirheumatic drug withdrawal in children with arthritis

Methotrexate users fail to achieve adequate immune response to mRNA COVID-19 vaccines

Methotrexate users fail to achieve adequate immune response to mRNA COVID-19 vaccines

People taking anti-inflammatory drug mount a weaker immune response to COVID-19 vaccine

People taking anti-inflammatory drug mount a weaker immune response to COVID-19 vaccine

Effect of COVID-19 pandemic on patients with rheumatoid arthritis, systemic lupus erythematosus

Effect of COVID-19 pandemic on patients with rheumatoid arthritis, systemic lupus erythematosus

Methotrexate impairs immunogenicity of BNT162b2 SARS-CoV-2 vaccine in patients with immune-mediated inflammatory diseases

Methotrexate impairs immunogenicity of BNT162b2 SARS-CoV-2 vaccine in patients with immune-mediated inflammatory diseases

Commonly-prescribed drug for IBD blunts COVID-19 vaccine response

Commonly-prescribed drug for IBD blunts COVID-19 vaccine response

Does natural infection with SARS-CoV-2 offer more protection than a vaccine against new variants?

Does natural infection with SARS-CoV-2 offer more protection than a vaccine against new variants?